BRAF V600E – Mutation, Diagnosis and Therapy
BRAF V600E is a common genetic mutation in the BRAF gene that can trigger uncontrolled cell growth and is found in various types of cancer.
Things worth knowing about "BRAF V600E"
BRAF V600E is a common genetic mutation in the BRAF gene that can trigger uncontrolled cell growth and is found in various types of cancer.
What is BRAF V600E?
BRAF V600E is the most common point mutation in the BRAF gene (B-Raf proto-oncogene). In this mutation, the amino acid valine (V) at position 600 of the BRAF protein sequence is replaced by glutamic acid (E). This change causes the BRAF protein to remain permanently active, continuously promoting cell growth without appropriate external signals. BRAF V600E is classified as an oncogenic driver mutation and plays a central role in modern cancer diagnostics and targeted therapy.
Biological Background
The BRAF gene encodes a serine-threonine kinase that is a key component of the MAPK/ERK signaling pathway (also known as the RAS-RAF-MEK-ERK pathway). Under normal conditions, this pathway regulates cell growth, division, and survival. The BRAF V600E mutation leads to constitutive activation of the downstream ERK signaling cascade, meaning the pathway is switched on permanently regardless of any growth signal. This results in uncontrolled cell proliferation – a hallmark of cancer development.
Occurrence in Cancer
BRAF V600E has been identified in a range of tumor types. The most clinically relevant include:
- Melanoma: Approximately 40–60% of all malignant melanomas carry the BRAF V600E mutation, making it the most common driver mutation in this cancer type.
- Papillary thyroid carcinoma: Present in approximately 40–45% of cases.
- Colorectal cancer: Found in approximately 8–12% of patients.
- Non-small cell lung cancer (NSCLC): Detected in approximately 1–3% of cases.
- Hairy cell leukemia: Present in nearly 100% of classic cases.
- Gliomas: Especially in pediatric pilocytic astrocytoma.
Diagnosis
Detection of the BRAF V600E mutation is performed using molecular diagnostic techniques, including:
- PCR-based methods (e.g., allele-specific PCR)
- Sanger sequencing
- Next-Generation Sequencing (NGS): Allows simultaneous analysis of multiple genes and is considered the current gold standard in tumor diagnostics.
- Immunohistochemistry (IHC): A specific antibody (VE1) directed against BRAF V600E is available for rapid screening on tissue sections.
Testing is performed on tumor tissue (biopsy or surgical resection specimen) or, increasingly, via liquid biopsy (circulating tumor DNA in blood).
Clinical Significance and Treatment
The identification of the BRAF V600E mutation has revolutionized targeted therapy for multiple cancer types. Specific inhibitors have been developed to block the activity of the mutated BRAF protein:
BRAF Inhibitors
- Vemurafenib (Zelboraf®)
- Dabrafenib (Tafinlar®)
- Encorafenib (Braftovi®)
These agents selectively bind to the mutated BRAF V600E protein and suppress its oncogenic activity. They are primarily used in advanced melanoma and have significantly improved patient outcomes.
Combination Therapies
Because resistance to BRAF inhibition alone frequently develops, combination with a MEK inhibitor is now the standard of care:
- Dabrafenib + Trametinib
- Vemurafenib + Cobimetinib
- Encorafenib + Binimetinib
These combinations delay the emergence of resistance and significantly improve overall survival. In BRAF V600E-mutated colorectal cancer, an EGFR inhibitor (e.g., cetuximab) is often added to the treatment regimen.
Side Effects of BRAF Inhibitors
Common side effects include:
- Skin reactions (e.g., rash, keratosis, secondary cutaneous squamous cell carcinomas)
- Joint and muscle pain
- Fatigue
- Elevated liver enzymes
- Fever (particularly with dabrafenib)
Prognostic Significance
The prognostic implications of a BRAF V600E mutation vary by tumor type. In melanoma, the mutation enables effective targeted therapy and substantially improves prognosis. In colorectal cancer, however, BRAF V600E is associated with a generally poor prognosis and influences treatment selection. In papillary thyroid carcinoma, the mutation is linked to a more aggressive disease course.
References
- Davies H. et al. - Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954. PubMed PMID: 12068308.
- Robert C. et al. - Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30-39.
- National Comprehensive Cancer Network (NCCN) - Clinical Practice Guidelines in Oncology: Melanoma. Version 2024. www.nccn.org.
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Verwandte Produkte
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.